NCT02419118View on ClinicalTrials.gov

"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

October 1, 2015

Study Completion Date

October 1, 2015

Conditions
Multiple Myeloma
Interventions
DRUG

Daratumumab

Treatment of myeloma patients with Daratumumab

DRUG

Lenalidomide

Treatment of myeloma patients

DRUG

Dexamethasone

Treatment of myeloma patients

Trial Locations (1)

7100

Department of Hematology Vejle Hospital, Vejle

All Listed Sponsors
lead

Vejle Hospital

OTHER

NCT02419118 - "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab " | Biotech Hunter | Biotech Hunter